Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells $98,762.50 in Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at $11,083,175. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Amicus Therapeutics Stock Up 0.1 %

FOLD stock opened at $10.99 on Friday. The stock’s 50 day simple moving average is $11.13 and its 200 day simple moving average is $10.61. Amicus Therapeutics, Inc. has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. The company has a market cap of $3.26 billion, a P/E ratio of -32.32 and a beta of 0.68.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $126.67 million during the quarter, compared to the consensus estimate of $121.21 million. Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The company’s quarterly revenue was up 34.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.15) earnings per share. On average, research analysts expect that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current fiscal year.

Institutional Trading of Amicus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC grew its holdings in shares of Amicus Therapeutics by 20.1% in the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock valued at $162,713,000 after acquiring an additional 2,307,385 shares in the last quarter. William Blair Investment Management LLC grew its holdings in Amicus Therapeutics by 12.8% during the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after purchasing an additional 1,477,084 shares during the period. Fiera Capital Corp grew its holdings in Amicus Therapeutics by 1.1% during the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after purchasing an additional 58,113 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Amicus Therapeutics by 14.3% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,020,536 shares of the biopharmaceutical company’s stock valued at $29,964,000 after purchasing an additional 378,999 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in Amicus Therapeutics by 17.9% during the second quarter. Victory Capital Management Inc. now owns 2,273,959 shares of the biopharmaceutical company’s stock valued at $22,558,000 after purchasing an additional 345,117 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on FOLD. Cantor Fitzgerald boosted their price objective on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday. Bank of America upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Guggenheim upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday. Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, Morgan Stanley reduced their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $17.50.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.